• Annetine C Gelijns, Alan J Moskowitz, Patrick T O'Gara, Gennaro Giustino, Michael J Mack, Donna M Mancini, Emilia Bagiella, Judy Hung, Gorav Ailawadi, Martin B Leon, Michael A Acker, John H Alexander, Neal W Dickert, Wendy C Taddei-Peters, and Marissa A Miller.
• Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, NY. Electronic address: Annetine.gelijns@mssm.edu.
• J. Thorac. Cardiovasc. Surg. 2021 Nov 1; 162 (5): 150415111504-1511.

ObjectivesTwo trials (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation Trial and Percutaneous Repair with the MitraClip Device for Severe Functional/Secondary Mitral Regurgitation Trial) were published in 2018 evaluating the effectiveness and safety of transcatheter repair for patients with heart failure with significant functional mitral regurgitation, which yielded different results. This article reviews the strength of the evidence, differences in trial designs, ethical and implementation implications, and delineates future research needs to help guide the appropriate dissemination of transcatheter repair for functional patients with mitral regurgitation.MethodsThe National Heart, Lung, and Blood Institute convened a workshop of interdisciplinary experts to address these objectives.ResultsTranscatheter repair of functional mitral regurgitation can provide significant benefits in terms of heart failure hospitalizations, survival, and quality of life when appropriate heart failure candidates with moderate to severe or severe mitral regurgitation while on optimal guideline-directed medical therapy can be identified. Key ingredients for success are preoperative evaluation and management and postoperative care by an interdisciplinary heart team.ConclusionsGiven the discordance observed between trials, ongoing innovation in patient management, and potential expansion of indications for use, the evidence base must be expanded to optimize appropriate implementation of this complex therapy. This will require more complete capture of outcome data in real-world settings for all eligible candidates whether or not they receive this therapy. Inevitably, the indications for use of this therapy will expand, as will the devices and therapeutic approaches for this population, necessitating the study of comparative effectiveness through randomized trials or observational studies. Moreover, given the substantial variations in care delivery, conducting implementation research to delineate characteristics of the optimal care model would be of benefit.Copyright © 2020. Published by Elsevier Inc.

28 keywords...

hide…